Articles from Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that it has completed the repurchase of $1 billion (1.9 million shares) of its common stock. As of December 3, 2024, $3 billion remained available under the company’s share repurchase authorization.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company’s existing repurchase authorization, of which $1 billion was remaining.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Wolfe Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on January 15, 2025, to shareholders of record as of December 13, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2024 before the market opens on Wednesday, October 23, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, hosted its 2024 Investor Day today and provided an in-depth review of the company’s proven growth strategy and its industry-leading businesses, which consistently deliver best-in-class products and services that are essential to the work performed by its customers around the world.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 8:30 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on October 15, 2024, to shareholders of record as of September 13, 2024.

To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. By testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing (NGS) technology, clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2024 before the market opens on Wednesday, July 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer”) to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs”), of Olink Holding AB (publ) (“Olink”) for $26.00 per Share and per ADS, in cash.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today released its 2023 Corporate Social Responsibility (CSR) report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on July 15, 2024, to shareholders of record as of June 14, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024 at 11:00 a.m. (ET).

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer") to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs” and, together with the Shares, the “Offer Securities”), of Olink Holding AB (publ) (“Olink”) for $26.00 per Share and per ADS, in cash.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer") to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs” and, together with the Shares, the “Offer Securities”), of Olink Holding AB (publ) (“Olink”) for $26.00 per Share and per ADS, in cash.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the TD Cowen Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. (EST).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on April 15, 2024, to shareholders of record as of March 15, 2024. This reflects an 11% increase over the previous dividend payment of $0.35.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer”) to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs” and, together with the Shares, the “Offer Securities”), of Olink Holding AB (publ) (“Olink”) for $26.00 per Share and per ADS, in cash.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2023 before the market opens on Wednesday, January 31, 2024, and will hold a conference call on the same day at 8:30 a.m. EST.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced a 15-year virtual power purchasing agreement (VPPA) with international solar developer ib vogt. Thermo Fisher’s 91-megawatt portion of the Serbal solar project will deliver approximately 192,000 megawatt hours of renewable electricity annually. Eurofins Scientific, a global leader in bioanalytical testing, collaborated in the aggregated deal for a 36-megawatt portion of the project.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer") to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs” and, together with the Shares, the “Offer Securities”), of Olink Holding AB (publ) (“Olink”) for $26.00 per Share and per ADS, in cash.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.5 billion aggregate principal amount (the “Offering”) of the following notes:

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company’s existing repurchase authorization, of which $1 billion was remaining.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on January 16, 2024, to shareholders of record as of December 15, 2023.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that Thermo Fisher has commenced the previously announced tender offer (the “Offer") through a direct, wholly owned subsidiary of Thermo Fisher (the “Buyer”) to acquire all of the outstanding common shares and all of the outstanding American Depositary Shares (“ADSs”) of Olink for $26.00 per common share and per ADS, in cash.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the third quarter ended September 30, 2023.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash. This represents a premium of approximately 74% to the closing price of Olink’s American Depositary Shares that trade on NASDAQ on October 16, 2023, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all of the American Depositary Shares. The transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2023 before the market opens on Wednesday, October 25, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, today announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC). The collaboration supports biopharmaceutical and biotech customers in meeting regulatory expectations to enroll and retain patients in clinical trials who more fully reflect real-world populations experiencing the disease or health condition being studied, including U.S. Food and Drug Administration requirements around diversity action plans.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Handelsbanken 3rd Annual Life Science Innovation Day on Wednesday, August 30th, 2023 at 10:00 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed the acquisition of CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash. Thermo Fisher announced the agreement to acquire CorEvitas on July 6, 2023.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.95 billion aggregate principal amount (the “Offering”) of the following notes, each issued at par:

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on October 13, 2023, to shareholders of record as of September 15, 2023.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced Jenny Johnson, president and chief executive officer of Franklin Resources, Inc. NYSE:BENNYSEBEN)

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definitive agreement to acquire CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2023 before the market opens on Wednesday, July 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyzer combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on July 14, 2023, to shareholders of record as of June 15, 2023.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, hosted its 2023 Investor Day today and provided an in-depth review of the Company’s proven growth strategy and its industry-leading businesses: Life Science Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Bernstein 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023 at 11:00 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers, the first and only immunoassays to receive breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, a severe pregnancy complication.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders and provides insight into its CSR progress and environmental, social and governance (ESG) efforts.

Pfizer and Thermo Fisher Scientific Inc. (NYSETMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient.1

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 11:00 a.m. (EDT).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will host its 2023 Investor Day on Wednesday, May 24, starting at 9:00 a.m. (ET)in New York City.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2023 before the market opens on Wednesday, April 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EST.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center’s Mission Bay campus.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Cowen Healthcare Conference on Monday, March 6, 2023 at 9:10 a.m. (EST).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per common share payable on April 14, 2023, to stockholders of record as of March 15, 2023. This reflects a 17% increase over the previous dividend payment of $0.30.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced it will power all of the company’s current U.S. sites with 100 percent renewable electricity by 2026. The company’s new 20-year virtual power purchasing agreement with EDF Renewables includes the full output of the 200-megawatt (MW) Millers Branch Solar project.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. (EST).

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2022 before the market opens on Wednesday, February 1, 2023, and will hold a conference call on the same day at 8:30 a.m. EST.

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates. Thermo Fisher announced the agreement to acquire The Binding Site on October 31, 2022.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, today announced a new 2030 greenhouse gas emissions reduction target to reduce its Scope 1 and 2 emissions from operations by more than 50% from a 2018 baseline.1 The company is on track to achieve its previous 2030 goal of a 30% reduction, ahead of schedule.

Thermo Fisher Scientific Inc. (NYSETMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).

Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher”) announced today that on November 14, 2022 it priced an offering of €1.25 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes: